Neurocrine Biosciencesvs.Regeneron
NBIX vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 5.3× larger than Neurocrine Biosciences by market cap; Regeneron trades at the lower P/E (17.6 vs 20.5); year to date, Neurocrine Biosciences leads (−0.4% vs −4.2%).
Side by side
| NBIX | REGN | |
|---|---|---|
| Market cap | $14.4B | $76.1B |
| Price | $142.44 | $746.54 |
| Today | +0.8% | +0.9% |
| Return YTD | −0.4% | −4.2% |
| Return 1Y | +1.6% | +31.2% |
| Since June 26, 2026 | −15.5% | +18.0% |
| P/E | 20.5 | 17.6 |
| P/S | 4.3 | 4.9 |
| P/B | 3.9 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More NBIX & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.